214 related articles for article (PubMed ID: 32284379)
21. La Crosse virus neuroinvasive disease - Missouri, 2009.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2010 Jul; 59(28):869-71. PubMed ID: 20651642
[TBL] [Abstract][Full Text] [Related]
22. La Crosse Virus in Aedes japonicus japonicus mosquitoes in the Appalachian Region, United States.
Harris MC; Dotseth EJ; Jackson BT; Zink SD; Marek PE; Kramer LD; Paulson SL; Hawley DM
Emerg Infect Dis; 2015 Apr; 21(4):646-9. PubMed ID: 25811131
[TBL] [Abstract][Full Text] [Related]
23. Lymphocytes have a role in protection, but not in pathogenesis, during La Crosse Virus infection in mice.
Winkler CW; Myers LM; Woods TA; Carmody AB; Taylor KG; Peterson KE
J Neuroinflammation; 2017 Mar; 14(1):62. PubMed ID: 28340587
[TBL] [Abstract][Full Text] [Related]
24. Severe La Crosse encephalitis with significant neurologic sequelae.
Balkhy HH; Schreiber JR
Pediatr Infect Dis J; 2000 Jan; 19(1):77-80. PubMed ID: 10643856
[TBL] [Abstract][Full Text] [Related]
25. Genome sequence analysis of La Crosse virus and in vitro and in vivo phenotypes.
Bennett RS; Ton DR; Hanson CT; Murphy BR; Whitehead SS
Virol J; 2007 May; 4():41. PubMed ID: 17488515
[TBL] [Abstract][Full Text] [Related]
26. The spatial epidemiology and clinical features of reported cases of La Crosse virus infection in West Virginia from 2003 to 2007.
Haddow AD; Bixler D; Odoi A
BMC Infect Dis; 2011 Jan; 11():29. PubMed ID: 21269495
[TBL] [Abstract][Full Text] [Related]
27. La Crosse virus (LACV) Gc fusion peptide mutants have impaired growth and fusion phenotypes, but remain neurotoxic.
Soldan SS; Hollidge BS; Wagner V; Weber F; González-Scarano F
Virology; 2010 Sep; 404(2):139-47. PubMed ID: 20553924
[TBL] [Abstract][Full Text] [Related]
28. Human neural stem cell-derived neuron/astrocyte co-cultures respond to La Crosse virus infection with proinflammatory cytokines and chemokines.
Dawes BE; Gao J; Atkins C; Nelson JT; Johnson K; Wu P; Freiberg AN
J Neuroinflammation; 2018 Nov; 15(1):315. PubMed ID: 30442185
[TBL] [Abstract][Full Text] [Related]
29. Cemeteries are effective sites for monitoring la crosse virus (LACv) and these environments may play a role in LACv infection.
Trout Fryxell RT; Freyman K; Ulloa A; Hendricks B; Paulsen D; Odoi A; Moncayo A
PLoS One; 2015; 10(4):e0122895. PubMed ID: 25860584
[TBL] [Abstract][Full Text] [Related]
30. Possible congenital infection with La Crosse encephalitis virus--West Virginia, 2006-2007.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2009 Jan; 58(1):4-7. PubMed ID: 19145220
[TBL] [Abstract][Full Text] [Related]
31. Protection from La Crosse virus encephalitis with recombinant glycoproteins: role of neutralizing anti-G1 antibodies.
Pekosz A; Griot C; Stillmock K; Nathanson N; Gonzalez-Scarano F
J Virol; 1995 Jun; 69(6):3475-81. PubMed ID: 7745694
[TBL] [Abstract][Full Text] [Related]
32. California-La Crosse encephalitis.
McJunkin JE; Khan RR; Tsai TF
Infect Dis Clin North Am; 1998 Mar; 12(1):83-93. PubMed ID: 9494831
[TBL] [Abstract][Full Text] [Related]
33. Effects of La Crosse virus infection on the host-seeking behavior and levels of two neurotransmitters in Aedes triseriatus.
Yang F; Chan K; Brewster CC; Paulson SL
Parasit Vectors; 2019 Aug; 12(1):397. PubMed ID: 31399119
[TBL] [Abstract][Full Text] [Related]
34. La Crosse viremias in Mongolian gerbils (Meriones unguiculatis).
Osorio JE; Yuill TM
Am J Trop Med Hyg; 1996 Nov; 55(5):567-9. PubMed ID: 8940992
[TBL] [Abstract][Full Text] [Related]
35. The incidence risk, clustering, and clinical presentation of La Crosse virus infections in the eastern United States, 2003-2007.
Haddow AD; Odoi A
PLoS One; 2009 Jul; 4(7):e6145. PubMed ID: 19582158
[TBL] [Abstract][Full Text] [Related]
36. DNA-based vaccine against La Crosse virus: protective immune response mediated by neutralizing antibodies and CD4+ T cells.
Schuh T; Schultz J; Moelling K; Pavlovic J
Hum Gene Ther; 1999 Jul; 10(10):1649-58. PubMed ID: 10428210
[TBL] [Abstract][Full Text] [Related]
37. Sirtuin Inhibitors Are Broadly Antiviral against Arboviruses.
Hackett BA; Dittmar M; Segrist E; Pittenger N; To J; Griesman T; Gordesky-Gold B; Schultz DC; Cherry S
mBio; 2019 Jul; 10(4):. PubMed ID: 31289184
[TBL] [Abstract][Full Text] [Related]
38. Mutagenesis of the La Crosse Virus glycoprotein supports a role for Gc (1066-1087) as the fusion peptide.
Plassmeyer ML; Soldan SS; Stachelek KM; Roth SM; Martín-García J; González-Scarano F
Virology; 2007 Feb; 358(2):273-82. PubMed ID: 17027056
[TBL] [Abstract][Full Text] [Related]
39. La Crosse bunyavirus nonstructural protein NSs serves to suppress the type I interferon system of mammalian hosts.
Blakqori G; Delhaye S; Habjan M; Blair CD; Sánchez-Vargas I; Olson KE; Attarzadeh-Yazdi G; Fragkoudis R; Kohl A; Kalinke U; Weiss S; Michiels T; Staeheli P; Weber F
J Virol; 2007 May; 81(10):4991-9. PubMed ID: 17344298
[TBL] [Abstract][Full Text] [Related]
40. The demographic and socioeconomic factors predictive for populations at high-risk for La Crosse virus infection in West Virginia.
Haddow AD; Bixler D; Schuh AJ
PLoS One; 2011; 6(9):e25739. PubMed ID: 21980533
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
